Hemogenyx posts deeper losses as CAR-T program pushes ahead in Europe and US
Hemogenyx Pharmaceuticals lost £6.56 million before tax in H1 2026, with £4.58 million left in cash, as it drives its CAR-T therapy into new clinical and commercial phases.
Europe & United Kingdom Biotech 1 article
Europe & United Kingdom Biotech follows companies, capital, clinical development, manufacturing and policy across European markets and the UK. EMA and MHRA frameworks, regional biotech hubs, financing and cross-border licensing are interpreted with attention to institutional differences inside the region. The section combines Europe and the United Kingdom for ecosystem coverage without treating their regulatory systems as identical; China and the wider Asia-Pacific region remain separate geographic categories.